| 1 | 1 | | 84R6961 PMO-F |
|---|
| 2 | 2 | | By: Raymond, Larson H.B. No. 2133 |
|---|
| 3 | 3 | | |
|---|
| 4 | 4 | | |
|---|
| 5 | 5 | | A BILL TO BE ENTITLED |
|---|
| 6 | 6 | | AN ACT |
|---|
| 7 | 7 | | relating to health benefit plan coverage for certain equipment and |
|---|
| 8 | 8 | | supplies associated with diabetes treatment. |
|---|
| 9 | 9 | | BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF TEXAS: |
|---|
| 10 | 10 | | SECTION 1. Sections 1358.051(1) and (2), Insurance Code, |
|---|
| 11 | 11 | | are amended to read as follows: |
|---|
| 12 | 12 | | (1) "Diabetes equipment" means: |
|---|
| 13 | 13 | | (A) blood glucose monitors, including |
|---|
| 14 | 14 | | noninvasive glucose monitors and glucose monitors designed to be |
|---|
| 15 | 15 | | used by blind individuals; |
|---|
| 16 | 16 | | (B) insulin pumps and associated supplies and |
|---|
| 17 | 17 | | appurtenances, including an insulin pump that works in conjunction |
|---|
| 18 | 18 | | with another medical device to provide automated or predictive |
|---|
| 19 | 19 | | insulin infusion suspend or control functionality as part of a |
|---|
| 20 | 20 | | system classified as an artificial pancreas device system by the |
|---|
| 21 | 21 | | United States Food and Drug Administration; |
|---|
| 22 | 22 | | (C) insulin infusion devices; [and] |
|---|
| 23 | 23 | | (D) podiatric appliances for the prevention of |
|---|
| 24 | 24 | | complications associated with diabetes; and |
|---|
| 25 | 25 | | (E) continuous glucose monitoring devices that |
|---|
| 26 | 26 | | continuously record glucose levels of individual users whether a |
|---|
| 27 | 27 | | freestanding device or integrated into an insulin pump. |
|---|
| 28 | 28 | | (2) "Diabetes supplies" means: |
|---|
| 29 | 29 | | (A) test strips for blood glucose monitors; |
|---|
| 30 | 30 | | (B) visual reading and urine test strips; |
|---|
| 31 | 31 | | (C) lancets and lancet devices; |
|---|
| 32 | 32 | | (D) insulin and insulin analogs; |
|---|
| 33 | 33 | | (E) injection aids; |
|---|
| 34 | 34 | | (F) syringes; |
|---|
| 35 | 35 | | (G) prescriptive and nonprescriptive oral agents |
|---|
| 36 | 36 | | for controlling blood sugar levels; [and] |
|---|
| 37 | 37 | | (H) glucagon emergency kits; and |
|---|
| 38 | 38 | | (I) supplies related to insulin pumps and |
|---|
| 39 | 39 | | continuous glucose monitoring devices, including insulin infusion |
|---|
| 40 | 40 | | sets, insulin reservoirs, glucose sensors, and glucose data |
|---|
| 41 | 41 | | transmitters. |
|---|
| 42 | 42 | | SECTION 2. This Act applies only to a health benefit plan |
|---|
| 43 | 43 | | that is delivered, issued for delivery, or renewed on or after |
|---|
| 44 | 44 | | September 1, 2015. A health benefit plan delivered, issued for |
|---|
| 45 | 45 | | delivery, or renewed before September 1, 2015, is governed by the |
|---|
| 46 | 46 | | law as it existed immediately before the effective date of this Act, |
|---|
| 47 | 47 | | and that law is continued in effect for that purpose. |
|---|
| 48 | 48 | | SECTION 3. This Act takes effect September 1, 2015. |
|---|